Cargando…

Modeling the Annual Costs of Postmenopausal Prevention Therapy: Raloxifene, Alendronate, or Estrogen-Progestin Therapy

OBJECTIVES: To estimate the annual cost and outcome impacts attributable to raloxifene, alendronate, and estrogen-progestin therapy as prevention therapies among postmenopausal women over the first 7 years of hormone replacement therapy (HRT). METHODS: A budget-impact model was devised to compare th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mullins, C. Daniel, Ohsfeldt, Robert L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2003
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437197/ https://www.ncbi.nlm.nih.gov/pubmed/14613344 http://dx.doi.org/10.18553/jmcp.2003.9.2.150

Ejemplares similares

Comparative evaluation of raloxifene versus estrogen: Progestin on symptomatology, endometrium, and lipid profile in postmenopausal women
por: Dogiparthi, Anuradha, et al.
Publicado: (2010)

Alendronate and Raloxifene Therapy in the Early Period after Hip Fracture
por: Ohishi, Tsuyoshi, et al.
Publicado: (2011)

Combination Therapy of Raloxifene and Alendronate for Treatment of Osteoporosis in Elderly Women
por: Um, Mi Jung, et al.
Publicado: (2017)

Postmenopausal estrogen and progestin effects on the serum proteome
por: Pitteri, Sharon J, et al.
Publicado: (2009)

Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia
por: Meadows, Eric S, et al.
Publicado: (2007)

Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials
por: Lin, Tiao, et al.
Publicado: (2014)

Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis
por: Kim, Yeesuk, et al.
Publicado: (2020)

Effects of the Combination Treatment of Raloxifene and Alendronate on the Biomechanical Properties of Vertebral Bone
por: Diab, Tamim, et al.
Publicado: (2011)

Ultrasonographic Observation of the Breast in Early Postmenopausal Women during Therapy with Cimicifuga Foetida Extract and Sequential Therapy with Estrogen and Progestin
por: Gaowa, Sharen, et al.
Publicado: (2015)

Estrogen–progestin replacement therapy: regulatory action needed
por: Pike, Malcolm C, et al.
Publicado: (2002)

Fractures in women treated with raloxifene or alendronate: a retrospective database analysis
por: Foster, Shonda A, et al.
Publicado: (2013)

Effects of combination treatment with alendronate and raloxifene on skeletal properties in a beagle dog model
por: Allen, Matthew R., et al.
Publicado: (2017)

Hemodynamic and metabolic effects of estrogen plus progestin therapy in hypertensive postmenopausal women treated with an ACE-inhibitor or a diuretic
por: Posadzy-Malaczynska, Anna, et al.
Publicado: (2014)

Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in Spain
por: Darbà, Josep, et al.
Publicado: (2013)

Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women
por: Ha, J., et al.
Publicado: (2022)

Quality of life and patient satisfaction with raloxifene/cholecalciferol combination therapy in postmenopausal women
por: Lee, Dong-Yun, et al.
Publicado: (2022)

A randomized trial of estrogen or raloxifene during postmenopausal weight loss: Adiposity and cardiometabolic outcomes
por: Van Pelt, R.E., et al.
Publicado: (2013)

Progestin and aromatase inhibitor therapy in recurrent, estrogen/progestin receptor positive uterine carcinosarcoma: A case report
por: Liang, Angela L., et al.
Publicado: (2021)

Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol
por: Bitto, A, et al.
Publicado: (2008)

Pharmacogenomics Study for Raloxifene in Postmenopausal Female with Osteoporosis
por: Lu, Hsing-Fang, et al.
Publicado: (2020)

Prevention of mammary carcinogenesis by short-term estrogen and progestin treatments
por: Rajkumar, Lakshmanaswamy, et al.
Publicado: (2004)

Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update
por: Messalli, Enrico M, et al.
Publicado: (2010)

Antileishmanial Activity of the Estrogen Receptor Modulator Raloxifene
por: Reimão, Juliana Q., et al.
Publicado: (2014)

Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine
por: Radwan, Asma, et al.
Publicado: (2022)

Effect of Raloxifene Treatment on Osteocyte Apoptosis in Postmenopausal Women
por: van Essen, Huib W., et al.
Publicado: (2007)

Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence
por: Chen, Mingsheng, et al.
Publicado: (2016)

Colorectal tumor prevention by the progestin medroxyprogesterone acetate is critically dependent on postmenopausal status
por: Meijer, Bartolomeus J., et al.
Publicado: (2018)

Positive association between mammographic breast density and bone mineral density in the Postmenopausal Estrogen/Progestin Interventions Study
por: Crandall, Carolyn, et al.
Publicado: (2005)

The role of counselling and other factors in compliance of postmenopausal osteoporotic patients to alendronate 70 therapy
por: Sewerynek, Ewa, et al.
Publicado: (2013)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Alendronate improves QOL of postmenopausal women with osteoporosis
por: Kawate, Hisaya, et al.
Publicado: (2010)

Progestin effects on cell proliferation pathways in the postmenopausal mammary gland
por: Wood, Charles E, et al.
Publicado: (2013)

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
por: Ebadi Fard Azar, Amir Ali, et al.
Publicado: (2017)

Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2020)

Anti-Estrogen Withdrawal Effect With Raloxifene? A Case Report
por: Lemmo, Walter
Publicado: (2016)

Endoscopic comparison of alendronate alone and the enteric-coated alendronate with calcitriol combination in postmenopausal Korean females
por: Mok, Ji Oh, et al.
Publicado: (2013)

Raloxifene/Vitamin D Combination Therapy vs. Raloxifene Monotherapy on Serum 25-Hydroxy-Vitamin D Level among Postmenopausal Women with Osteoporosis or Osteopenia: A Randomized Controlled Trial
por: Lee, You-Bin, et al.
Publicado: (2022)

Progestins: Pro-senescence therapy for ovarian cancer?
por: Oesterreich, Steffi, et al.
Publicado: (2013)

Comparison of Effects of Alendronate and Raloxifene on Lumbar Bone Mineral Density, Bone Turnover, and Lipid Metabolism in Elderly Women with Osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2008)

An Observational Study to Assess the Safety and Efficacy on Quality of Life and Patient Satisfaction With Raloxifene/Cholecalciferol Combination Therapy in Postmenopausal Women Requiring Prevention or Treatment for Osteoporosis
por: Chung, Yoon-Sok, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j4aj95m09ql1p59dqojetptikb